Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03284333 · ClinicalTrials.gov registry record · NA
enLighten Laser With MLA Handpiece for Treatment of Moderate and Severe Acne Scars
A NA study of Acne Scars - Mixed Atrophic and Hypertrophic, sponsored by Cutera.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 2
- Study locations
NCT03284333: Completed NA study of Acne Scars - Mixed Atrophic and Hypertrophic, sponsored by Cutera.
NCT03284333 is a NA study of Acne Scars - Mixed Atrophic and Hypertrophic that has completed, run by Cutera. The registered enrollment target is 45 participants, below the 105-participant average among 7 other Acne Scars - Mixed Atrophic and Hypertrophic trials with a reported enrollment target (57% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03284333, a NA study of Acne Scars - Mixed Atrophic and Hypertrophic, has completed, sponsored by Cutera.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this pivotal investigation is to evaluate the efficacy and safety of the Cutera enlighten multi-wavelength 532 nm and 1064 nm Nd:YAG picosecond pulse duration laser and an investigational micro-lens array (MLA) handpiece attachment for improvement of acne scars.
Primary Outcome
visual review of study photographs correctly identifying the temporal order (before and after) of each photograph pair (Baseline and 12 week Post-final treatment)
Conditions Studied
Interventions
- DEVICE other
Study Locations (2)
California
- Cutera Research Center - Brisbane
New York
- Sadick Dermatology/Sadick Research Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2017-07-27 |
| Est. Completion | 2018-09-05 |
| Phase | NA |
What the finished NCT03284333 record still lists
NCT03284333 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 105-participant average among 7 other Acne Scars - Mixed Atrophic and Hypertrophic trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Acne Scars - Mixed Atrophic and Hypertrophic appearing as the primary indexed condition, and to 1 intervention - of which other is the first listed.
NCT03284333 reports a single indexed study location in California, New York.
Frequently Asked Questions
What is clinical trial NCT03284333 about?
NCT03284333 is a clinical study titled "enLighten Laser With MLA Handpiece for Treatment of Moderate and Severe Acne Scars". The purpose of this pivotal investigation is to evaluate the efficacy and safety of the Cutera enlighten multi-wavelength 532 nm and 1064 nm Nd:YAG picosecond pulse duration laser and an investigational micro-lens array (MLA) handpiece attachment for improvement of acne scars.
What is the current status of trial NCT03284333?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2017-07-27. Estimated completion is 2018-09-05.
What conditions does trial NCT03284333 study?
This clinical trial studies the following conditions: Acne Scars - Mixed Atrophic and Hypertrophic.
What interventions are being tested in trial NCT03284333?
The interventions under investigation include: other (DEVICE).
Who is sponsoring clinical trial NCT03284333?
This trial is sponsored by Cutera, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03284333 being conducted?
This trial has 2 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Scars - Mixed Atrophic and Hypertrophic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AVAVA MIRIA General Use
RECRUITING · NA
-
Efficacy and Tolerability of a Hybrid Fractional Laser for the Treatment of Acne Scars in Patients With Skin of Color
RECRUITING · NA
-
The MIRIA Acne Scar Study
ACTIVE NOT RECRUITING · NA
-
AV-23-001 AVAVA MIRIA Pilot Study
ACTIVE NOT RECRUITING · NA
-
Tripeptide/Hexapeptide Topical and Hybrid Laser Treatment for Acne Scarring
COMPLETED · NA
-
Functional Usability and Feasibility Testing of the Profound Matrix™ System
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI